Research progress of stem cells in Mycobacterium tuberculosis infection

doi:10.3969/j.issn.1000-6621.2021.02.015

Abstract

Abstract:

Tuberculosis is mainly caused by an intracellular pathogen—Mycobacterium tuberculosis, which can lurk or proliferate in host cells. It can also invade stem cells such as hematopoietic stem cells and mesenchymal stem cells. Stem cells are capable of self-replication, pluripotent differentiation, high migration and immune regulation, thus the role of them in the occurrence and development of tuberculosis can not be ignored. We mainly reviewed the pathogenesis and prevention and treatment strategies of tuberculosis through the interaction between Mycobacterium tuberculosis and stem cells.

Key words: Stem cells, Mycobacterium tuberculosis, Transactional analysis, Tuberculosis, Immunomodulation

GUO Qian, SHEN Chen, SHEN A-dong. Research progress of stem cells in Mycobacterium tuberculosis infection[J]. Chinese Journal of Antituberculosis, 2021, 43(2): 186-189. doi: 10.3969/j.issn.1000-6621.2021.02.015

References 35

[1]	Agarwal N, Lamichhane G, Gupta R, et al. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature, 2009,460(7251):98-102. doi: 10.1038/nature08123.
[2]	Debes AK, Gilman RH, Onyango-Makumbi C, et al. Cost-effectiveness of Diagnostic Algorithms for Tuberculosis in Children Less Than 5 Years of Age. Pediatr Infect Dis J, 2017,36(1):36-43. doi: 10.1097/INF.0000000000001342.
[3]	Lovewell RR, Sassetti CM, VanderVen BC. Chewing the fat: lipid metabolism and homeostasis during M.tuberculosis infection. Curr Opin Microbiol, 2016,29:30-36. doi: 10.1016/j.mib.2015.10.002.
[4]	Beamer G, Major S, Das B, et al. Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment. Am J Pathol, 2014,184(12):3170-3175. doi: 10.1016/j.ajpath.2014.08.024.
[5]	Reece ST, Vogelzang A, Tornack J, et al. Mycobacterium tuberculosis-Infected Hematopoietic Stem and Progenitor Cells Unable to Express Inducible Nitric Oxide Synthase Propagate Tuberculosis in Mice. J Infect Dis, 2018,217(10):1667-1671. doi: 10.1093/infdis/jiy041.
[6]	Tornack J, Reece ST, Bauer WM, et al. Human and Mouse Hematopoietic Stem Cells Are a Depot for Dormant Mycobacterium tuberculosis. PLoS One, 2017,12(1):e169119. doi: 10.1371/journal.pone.0169119.
[7]	Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell, 2007,131(2):324-336. doi: 10.1016/j.cell.2007.08.025.
[8]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09.
[9]	Raghuvanshi S, Sharma P, Singh S, et al. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci U S A, 2010,107(50):21653-21658. doi: 10.1073/pnas.1007967107.
[10]	Jain N, Kalam H, Singh L, et al. Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis. Nat Commun, 2020,11(1):3062. doi: 10.1038/s41467-020-16877-3.
[11]	Das B, Kashino SS, Pulu I, et al. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med, 2013,5(170):113r-170r. doi: 10.1126/scitranslmed.3004912.
[12]	Pascutti MF, Erkelens MN, Nolte MA. Impact of Viral Infections on Hematopoiesis: From Beneficial to Detrimental Effects on Bone Marrow Output. Front Immunol, 2016,7:364. doi: 10.3389/fimmu.2016.00364.
[13]	Bonomo A, Monteiro AC, Goncalves-Silva T, et al. A T Cell View of the Bone Marrow. Front Immunol, 2016,7:184. doi: 10.3389/fimmu.2016.00184.
[14]	Lee HJ, Lee DG, Choi SM, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS One, 2017,12(3):e173250. doi: 10.1371/journal.pone.0173250.
[15]	Aguado JM, Silva JT, Samanta P, et al. Tuberculosis and Transplantation. Microbiology Spectrum, 2016,4(6). doi: 10.1128/microbiolspec.TNMI7-0005-2016.
[16]	Simmons JD, Stein CM, Seshadri C, et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat Rev Immunol, 2018,18(9):575-589. doi: 10.1038/s41577-018-0025-3.
[17]	Giampaolo S, Wojcik G, Serfling E, et al. Interleukin-2-regulatory T cell axis critically regulates maintenance of hematopoietic stem cells. Oncotarget, 2017,8(18):29625-29642. doi: 10.18632/oncotarget.16377.
[18]	Li F, Liu X, Niu H, et al. Persistent stimulation with Mycobacterium tuberculosis antigen impairs the proliferation and transcriptional program of hematopoietic cells in bone marrow. Mol Immunol, 2019,112:115-122. doi: 10.1016/j.molimm.2019.05.001.
[19]	McCabe A, Zhang Y, Thai V, et al. Macrophage-Lineage Cells Negatively Regulate the Hematopoietic Stem Cell Pool in Response to Interferon Gamma at Steady State and During Infection. Stem Cells, 2015,33(7):2294-2305. doi: 10.1002/stem.2040.
[20]	Matatall KA, Jeong M, Chen S, et al. Chronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation. Cell Rep, 2016,17(10):2584-2595. doi: 10.1016/j.celrep.2016.11.031.
[21]	Kaufmann E, Sanz J, Dunn JL, et al. BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. Cell, 2018,172(1/2):176-190. doi: 10.1016/j.cell.2017.12.031.
[22]	Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT(R)) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019,21(10):1019-1024. doi: 10.1016/j.jcyt.2019.08.002.
[23]	Mastrolia I, Foppiani EM, Murgia A, et al. Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review. Stem Cells Transl Med, 2019,8(11):1135-1148. doi: 10.1002/sctm.19-0044.
[24]	Saalbach A, Anderegg U. Thy-1: more than a marker for mesenchymal stromal cells. FASEB J, 2019,33(6):6689-6696. doi: 10.1096/fj.201802224R.
[25]	Hampshire T, Soneji S, Bacon J, et al. Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb), 2004,84(3/4):228-238. doi: 10.1016/j.tube.2003.12.010.
[26]	Fatima S, Kamble SS, Dwivedi VP, et al. Mycobacterium tuberculosis programs mesenchymal stem cells to establish dormancy and persistence. J Clin Invest, 2020,130(2):655-661. doi: 10.1172/JCI128043.
[27]	Khan A, Mann L, Papanna R, et al. Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy. Sci Rep, 2017,7(1):15010. doi: 10.1038/s41598-017-15290-z.
[28]	Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020,577(7788):95-102. doi: 10.1038/s41586-019-1817-8.
[29]	Hetzel M, Mucci A, Blank P, et al. Hematopoietic stem cell gene therapy for IFNgammaR1 deficiency protects mice from mycobacterial infections. Blood, 2018,131(5):533-545. doi: 10.1182/blood-2017-10-812859.
[30]	Khan A, Hunter RL, Jagannath C. Emerging role of mesenchymal stem cells during tuberculosis: The fifth element in cell mediated immunity. Tuberculosis (Edinb), 2016,101S:S45-S52. doi: 10.1016/j.tube.2016.09.019.
[31]	Choi HG, Choi S, Back YW, et al. Mycobacterium tuberculosis Rv2882c Protein Induces Activation of Macrophages through TLR4 and Exhibits Vaccine Potential. PLoS One, 2016,11(10):e164458. doi: 10.1371/journal.pone.0164458.
[32]	Yudintceva NM, Bogolyubova IO, Muraviov AN, et al. Application of the allogenic mesenchymal stem cells in the therapy of the bladder tuberculosis. J Tissue Eng Regen Med, 2018,12(3):e1580-e1593. doi: 10.1002/term.2583.
[33]	Zangi L, Margalit R, Reich-Zeliger S, et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells, 2009,27(11):2865-2874. doi: 10.1002/stem.217.
[34]	Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med, 2014,2(2):108-122. doi: 10.1016/S2213-2600(13)70234-0.
[35]	Han HW, Seo HH, Jo HY, et al. Drug Discovery Platform Targeting M.tuberculosis with Human Embryonic Stem Cell-Derived Macrophages. Stem Cell Reports, 2019,13(6):980-991. doi: 10.1016/j.stemcr.2019.10.002.